Wednesday, Oragenics Inc. (NYSE:OGEN) announced the completion of its spray-dried formulation and filling in the nasal device for its lead candidate, ONP-002, for concussion. Oragenics is a development-stage biotechnology company focused on nasal delivery of pharmaceutical medications for infectious diseases and neurological conditions, including drug candidates for mild traumatic brain injury (mTBI), also known as concussion, and Niemann Pick Disease Type C (NPC), as well as proprietary powder formulation and an intranasal delivery device. Also Read: EXCLUSIVE: Oragenics’ Concussion Drug Clea…
